Clinical Trials Logo

Filter by:
NCT ID: NCT05868083 Recruiting - Clinical trials for Recurrent Glioblastoma Multiforme

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Start date: June 24, 2022
Phase: Phase 1
Study type: Interventional

This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness, the immunogenicity of the product, as well as their correlation between the changes of cytokines from baseline level after cellular infusion.

NCT ID: NCT05867901 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Start date: June 1, 2023
Phase:
Study type: Observational

This study is aimed: - to evaluate the dynamic monitoring value of MRD detection for postoperative recurrence in high-risk GIST patients; - to evaluate the effect of drug holiday mode based on MRD detection on progression-free Survival (PFS) and/or overall survival (OS) after drug withdrawal for high-risk GIST patients who have achieved disease control after long-term use of imatinib; ③ to investigate the response rate of imatinib re-use in patients who developed disease progression after drug withdrawal; ④ to explore whether the "drug holiday" treatment mode based on MRD detection could delay the occurrence of secondary imatinib resistance mutations for high-risk GIST patients with long-term use of imatinib after surgery.

NCT ID: NCT05867771 Recruiting - Advanced Tumors Clinical Trials

A Study of PM1022 in Patients With Advanced Tumors

Start date: April 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study incluces a phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM1022 in patients with advanced tumors and a phase IIa study to investigate the efficacy of PM1022 in patients with advanced tumors.

NCT ID: NCT05867589 Recruiting - Myocardial Fibrosis Clinical Trials

Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety of fibroblast activating protein receptor imaging agent [68Ga]/ Fluorine [18F] -fibroblast activating protein inhibitor (68Ga/18F-FAPI-04) in clinical application and to verify its effectiveness in the diagnosis of cardiovascular diseases.

NCT ID: NCT05867563 Recruiting - Clinical trials for Advanced Malignant Neoplasm

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Start date: July 4, 2023
Phase: Phase 1
Study type: Interventional

TQB2103 injection is an antibody-drug conjugate (ADC) targeting claudin (CLDN) 18.2. This study aimed to evaluate the safety and tolerability, pharmacokinetic characteristics and immunogenicity of TQB2103 injection in patients with advanced malignant tumors as well as its initial effectiveness.

NCT ID: NCT05867303 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Start date: June 5, 2023
Phase: Phase 1
Study type: Interventional

Safety study of RC198 in Subjects with Solid Tumors.

NCT ID: NCT05866692 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: August 17, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.

NCT ID: NCT05866510 Recruiting - Esophageal Cancer Clinical Trials

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Start date: May 15, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.

NCT ID: NCT05866172 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Start date: May 10, 2023
Phase: Phase 3
Study type: Interventional

Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable hepatocellular carcinoma.

NCT ID: NCT05865977 Recruiting - Premature Clinical Trials

dTDI During a SBT to Predict Extubation Failure in Preterm Infants

Start date: February 25, 2023
Phase:
Study type: Observational

Weaning from mechanical ventilation is a critical issue and the diaphragmatic disfunction has been demonstrated to play an important role in extubation failure. the aim of present investigation is to evaluate diaphragmatic excursion velocity during in patients undergoing spontaneous breathing trial through tissue Doppler analysis in both inspiration and expiration.